These three drugs have been shown to be ineffective in treating COVID-19
- Blood drop detection of miRNAs can diagnose early lung cancer
- Will people be arrested if refusing treatment after contracting tuberculosis?
- Vitamin D supplementation may help strengthen Long-COVID recovery
- What bacteria and viruses can cause cancers?
- The world first TIL cell therapy targeting advanced melanoma is coming soon
- The Pros and Cons of Radiotherapy Affecting Antitumor Immunity
These three drugs have been shown to be ineffective in treating COVID-19
- Hmpv is raging across the United States and the death rate is as high as 43%!
- COVID “Arcturus” XBB.1.16: The first death in U.S.
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
These three drugs have been shown to be ineffective in treating COVID-19.In the face of the sudden outbreak of COVID-19, the new use of old drugs has become the main way to find treatment options for COVID-19.
Through rigorous clinical research design: randomized, double-blind, placebo-controlled large-sample multi-center clinical trials, medical scientists have found a series of old drugs that reduce the mortality rate of severe COVID-19 patients, the most typical of which is dexamethasone, which is cheap Another easy-to-obtain old drug: the clinical trial results are released at noon, and the UK will be promoted nationwide in the afternoon.
However, more older medicines have proven ineffective for quality COVID-19.
On August 18, 2022, the COVID-OUT clinical research group led by the University of Minnesota reported in the New England Journal of Medicine (NEJM) the results of a large-scale clinical trial of the new use of old drugs to treat COVID-19 [1].
This large randomized placebo-controlled Phase 3 clinical trial (NCT04510194) evaluated 3 of the frequently discussed drugs: metformin, ivermectin and fluvoxamine. 1323 patients with COVID-19 shortly after diagnosis were enrolled, with a median age of 46 years and 56% women. 52% were vaccinated.
The study found that compared with the control group, the adjusted risk factors for disease progression after metformin use aOR=0.84, p=0.19; ivermectin aOR=1.05, p=0.78; fluvoxamine aOR=0.94, p=0.75. None of the three drugs had a significant benefit in improving patient symptoms and clinical manifestations.
The study further found that there was no significant reduction in hospitalization and death among patients receiving the three drugs, aOR=0.47; ivermectin aOR=0.73; fluvoxamine aOR=1.11.
Summary:
The study found that none of the three drugs , metformin, ivermectin, and fluvoxamine, improved symptoms early at diagnosis, nor did they reduce hospitalizations and deaths.
For a new disease such as COVID-19, doctors can only diagnose and treat based on the consensus formed by the best evidence currently available at the beginning; then adjust or improve it when new evidence is available.
In the process of repeated verification, especially relying on the results of RCT research, medicine has been advanced; finally, empirical medicine has been transformed into evidence-based medicine.
Related news:
NEJM: Metformin can effectively reduce the risk of severe COVID-19
References:
[ 1] https://www.nejm.org/doi/full/10.1056/NEJMoa2201662
(source:internet, reference only)
Disclaimer of medicaltrend.org